REN and hyperlipidemia: Hyperlipidemia [before excluding a single study[12] (p = 0.66, I2 = 90%); after excluding the study (p< 0.0001, I2 = 0%)], Renin angiotensin-converting enzyme inhibitorsshowed high heterogeneity [before excluding a single study [13] (p =0.58, I2 = 89%); after excluding the study (p = 0.23, I2 =74%)], and female gender [before excluding a single study [12] (p =0.27, I2 = 83%); after excluding the study (p < 0.00001, I2= 41%)], there were changes observed.